Arrowhead Research reported $-22206000 in EBITDA for its fourth fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agios Pharmaceuticals AGIO:US $ -89.76M 1.83M
Alnylam Pharmaceuticals ALNY:US $ -183.84M 32.79M
Arena Pharmaceuticals ARNA:US $ -134.34M 36.52M
Arrowhead Research ARWR:US $ -22206000 26.14M
Bluebird Bio BLUE:US $ -199.88M 14.31M
Cerulean Pharma CERU:US $ -7.57M 0.46M
Dicerna Pharmaceuticals DRNA:US $ -31.04M 8.69M
Heron Therapeutics HRTX:US $ -60.58M 2.97M
Intercept Pharmaceuticals ICPT:US $ -39.15M 3.33M
Ligand Pharmaceuticals LGND:US $ 7.14M 1.38M
Merk MRK:US $ 1187M 3475M
Mirati Therapeutics MRTX:US $ -106.13M 17.63M
Moderna Inc MRNA:US -267332000 40.71M
Nektar Therapeutics NKTR:US $ -107.48M 7.67M
Novartis NOVN:VX SF 4270M 790M
Opko Health OPK:US $ 69.45M 26.54M
Ultragenyx Pharmaceutical RARE:US $ -92.95M 45.72M
Vertex Pharmaceuticals VRTX:US $ 775.65M 74.96M
Xencor XNCR:US $ -12.17M 3.11M
YTE INCY:US $ 193.42M 153.05M